STICHTING EUROPEAN CLINICAL RESEARCH ALLIANCE ON INFECTIOUS DISEASES

Their core work

ECRAID is a Netherlands-based foundation that serves as Europe's coordinating platform for clinical research on infectious diseases. They organize and accelerate clinical trials — particularly vaccine trials — across European research sites, building the infrastructure needed for rapid response during outbreaks. Their core value lies in connecting clinical research networks across countries, standardizing data collection, and ensuring Europe can mobilize large-scale trials quickly when a new pathogen emerges. They also work on antimicrobial resistance research and infection prevention strategies in clinical settings.

What they specialise in

How they've shifted over time

ECRAID's H2020 activity spans only 2019–2021 (project start dates), making this a relatively compressed timeline. Their earliest projects (VITAL, RECoVER) focused on vaccination response in aging populations and emergency SARS-CoV-2 clinical research — clearly shaped by the COVID-19 pandemic. Their later projects (ECRAID-Base, NeoIPC, PrIMAVeRa) shift toward long-term infrastructure: building a permanent European clinical research platform, tackling antimicrobial resistance, and strengthening infection prevention in hospitals. The trajectory moves from reactive pandemic response toward sustained, structured preparedness.

ECRAID is transitioning from COVID-era emergency research toward becoming Europe's permanent backbone for infectious disease clinical trials and AMR prevention.

How they like to work

ECRAID primarily operates as a participant (5 of 6 projects), joining large consortia rather than leading them — though their one coordinated project (ECRAID-Base) is by far their largest at EUR 4.4M, suggesting they lead when it's their core mission. With 92 unique partners across 30 countries, they function as a network hub connecting diverse clinical research sites across Europe. This broad network makes them an attractive partner for anyone needing pan-European clinical trial reach.

ECRAID has built an exceptionally wide network of 92 unique consortium partners across 30 countries, reflecting their role as a pan-European clinical research connector. Their reach spans nearly all EU member states and likely extends to associated countries, making them one of the more broadly connected organizations in infectious disease research.

What sets them apart

ECRAID is not a university lab or a pharma company — it is a purpose-built European alliance designed to coordinate clinical research on infectious diseases at continental scale. Their unique value is organizational: they provide a single entry point to a network of clinical trial sites across 30 countries, which no individual institution can offer. For anyone needing to run multi-site infectious disease trials in Europe or seeking a partner with ready access to diverse clinical populations, ECRAID is the infrastructure layer that makes it possible.

Highlights from their portfolio

• ECRAID-Base
  Their flagship project (EUR 4.4M, sole coordinator role) — builds the permanent European infrastructure for infectious disease clinical research coordination.
• VACCELERATE
  Pan-European COVID-19 vaccine trial accelerator with site mapping and volunteer registry — demonstrated ECRAID's ability to mobilize clinical trial networks under pressure.
• PrIMAVeRa
  Forward-looking AMR project using mathematical modelling to predict how vaccines and monoclonal antibodies affect antibiotic resistance — signals ECRAID's strategic shift beyond pandemic response.